Remove tag biologics
article thumbnail

BD partners with Biocorp on connected self-injection devices

pharmaphorum

Medtech giant Beckton Dickinson (BD) has signed a deal with France’s Biocorp to use the latter’s near-field communication (NFC) tags in injectable devices. The Injay tag can confirm a complete injection and transfer that information via an NFC reader to a smartphone or tablet for review by a healthcare professional.

article thumbnail

New purification method could enhance protein drug manufacturing

European Pharmaceutical Review

Producing biologics by isolating proteins Biologics like antibodies and other protein-based drugs are produced by living cells such as yeast in large bioreactors. The authors explained that these are commonly used for tagging proteins for study or attaching protein drugs to drug-delivering nanoparticles.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Actualising the power of antibody-drug conjugates as cancer therapeutics

European Pharmaceutical Review

tag ® , inspired by the unique features of microtubule biology and perfectly suited for DAR 2 and DAR 4 ADCs. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Since then, the pace of approvals has increased in line with maturing technologies, resulting in 11 additional ADC approvals between 2017 and 2021.

article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. While Vertex and CRISPR submitted the Biologics License Application (BLA) for exa-cel earlier this April, bluebird has yet to do so for lovo-cel.

article thumbnail

Q&A: A decade on, what’s next for CAR-T therapies?

Pharmaceutical Technology

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics. But there is that significant challenge. There has been extremely rapid progress.

article thumbnail

You can’t afford to get cancer

World of DTC Marketing

As cancer survival rates rise, so do the price tags of life-saving treatments. OPENING: American cancer patients spent more than $21 billion on their care in 2019. billion included out-of-pocket costs of $16.22 billion and patient time costs of $4.87 Major cancer studies can’t be replicated .